Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LSTA
Upturn stock ratingUpturn stock rating

Lisata Therapeutics Inc. (LSTA)

Upturn stock ratingUpturn stock rating
$2.51
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: LSTA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -45.59%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 20.99M USD
Price to earnings Ratio -
1Y Target Price 14.33
Price to earnings Ratio -
1Y Target Price 14.33
Volume (30-day avg) 67554
Beta 1.15
52 Weeks Range 2.19 - 4.20
Updated Date 02/18/2025
52 Weeks Range 2.19 - 4.20
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.51

Earnings Date

Report Date 2025-02-26
When After Market
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.49%
Return on Equity (TTM) -48.15%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -14603794
Price to Sales(TTM) -
Enterprise Value -14603794
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.82
Shares Outstanding 8394900
Shares Floating 6718021
Shares Outstanding 8394900
Shares Floating 6718021
Percent Insiders 19.25
Percent Institutions 9.36

AI Summary

Lisata Therapeutics Inc.: A Comprehensive Overview

Company Profile

Detailed History and Background:

Lisata Therapeutics Inc. (NASDAQ: LSTA) is a clinical-stage biopharmaceutical company specializing in developing novel antibody-based therapies for the treatment of severe and life-threatening bleeding disorders. Founded in 2014, Lisata is headquartered in Waltham, Massachusetts, and has additional research and development facilities in California. They leverage their proprietary ADAPTIR™ technology platform to design and develop engineered protein therapeutics with improved efficacy and safety profiles.

Core Business Areas:

Lisata's primary focus is on developing treatments for hemophilia A and B, two rare genetic disorders characterized by deficient or dysfunctional clotting factors. Their lead product candidate, LST-002, is a bispecific antibody targeting both Factor VIII and Factor IX, aiming to provide comprehensive protection against bleeding episodes in patients with hemophilia A and B. Additionally, the company has a preclinical program exploring Factor XI-directed therapies for hemophilia C and other bleeding disorders.

Leadership Team and Corporate Structure:

Lisata's leadership team comprises experienced executives with extensive expertise in drug development and commercialization. Dr. Lee Henderson serves as the President and Chief Executive Officer, and Dr. Christopher Morabito is the Chief Medical Officer. The company operates with a Board of Directors and a Scientific Advisory Board, providing strategic guidance and oversight.

Top Products and Market Share:

Top Products and Offerings:

Lisata's flagship product is LST-002, currently in Phase 2 clinical trials. This bispecific antibody targets both Factor VIII and Factor IX, offering the potential for comprehensive bleed protection in hemophilia A and B patients. The company also holds intellectual property rights for several other preclinical programs targeting Factor XI and other clotting factors.

Market Share:

The global hemophilia market is estimated to reach $16.7 billion by 2027, with Factor VIII replacement therapies accounting for the largest segment. Lisata's LST-002, if successful, could potentially capture a significant share of this market by offering a more convenient and effective treatment option for patients with hemophilia A and B.

Product Performance and Market Reception:

LST-002 has demonstrated promising results in Phase 1 clinical trials, showing a favorable safety profile and extended half-life compared to existing therapies. Phase 2 trials are ongoing to further evaluate its efficacy and safety in a larger patient population. Initial market reception has been positive, with investors and analysts recognizing the potential of LST-002 to address unmet needs in the hemophilia market.

Total Addressable Market:

The global market for hemophilia treatments is expected to reach $16.7 billion by 2027. Within this market, Factor VIII replacement therapies represent the largest segment, with an estimated value of $10.5 billion in 2022. Lisata's LST-002, if approved, would compete directly in this segment, aiming to offer a more effective and convenient treatment option for patients with hemophilia A and B.

Financial Performance:

Recent Financial Performance:

Lisata is a clinical-stage company and has not yet generated any product revenue. As of September 30, 2023, the company had cash and cash equivalents of $173.7 million, which is expected to fund operations through 2024. The company's net loss for the nine months ended September 30, 2023, was $47.4 million, primarily driven by research and development expenses related to ongoing clinical trials.

Year-over-Year Comparison:

Lisata's net loss has increased compared to the same period in 2022, primarily due to higher research and development expenses associated with advancing LST-002 into Phase 2 clinical trials. The company's cash position has remained relatively stable, indicating efficient cash management.

Cash Flow and Balance Sheet Health:

Lisata's cash flow is primarily driven by financing activities, as the company is not yet generating revenue. The company has a sound balance sheet with a low debt-to-equity ratio, indicating a healthy financial position.

Dividends and Shareholder Returns:

Dividend History:

Lisata does not currently pay dividends, as it is a clinical-stage company focused on investing in research and development.

Shareholder Returns:

Lisata's stock price has experienced significant volatility since its initial public offering in 2021. Year-to-date, the stock is down approximately 20%, reflecting the overall market downturn and uncertainty surrounding the company's clinical development programs. However, over a longer timeframe, the stock has the potential to generate substantial returns if LST-002 is successfully developed and commercialized.

Growth Trajectory:

Historical Growth:

Lisata has experienced rapid growth since its founding in 2014. The company has successfully raised significant capital, advanced its lead product candidate into Phase 2 clinical trials, and expanded its research and development capabilities.

Future Growth Projections:

Lisata's future growth will depend on the success of LST-002 in clinical development and its subsequent commercialization. The company's management projects peak sales potential of over $1 billion for LST-002 if approved. Additionally, Lisata's preclinical programs have the potential to generate further growth opportunities in the future.

Recent Product Launches and Strategic Initiatives:

Lisata's primary focus remains on advancing LST-002 through clinical trials. The company is actively seeking partnerships and collaborations to support the development and commercialization of its product candidates.

Market Dynamics:

Industry Overview:

The hemophilia treatment market is characterized by rapid innovation and intense competition. Several large pharmaceutical companies and emerging biotechnology firms are developing novel therapies for hemophilia A and B. The market is expected to continue experiencing strong growth driven by increasing awareness, improved diagnosis, and the development of more effective and convenient treatment options.

Industry Positioning:

Lisata is well-positioned within the hemophilia market with its innovative ADAPTIR™ technology platform and promising lead product candidate, LST-002. The company's focus on developing a comprehensive treatment option for hemophilia A and B differentiates it from competitors who primarily offer Factor VIII or Factor IX replacement therapies.

Adaptability to Market Changes:

Lisata continuously monitors the hemophilia market and adapts its strategies to capitalize on emerging trends and opportunities. The company's involvement in collaborative partnerships and its commitment to developing innovative therapies demonstrate its adaptability to the dynamic hemophilia market.

Competitors:

Key Competitors:

Several major pharmaceutical companies are developing hemophilia treatments, including:

  • BioMarin Pharmaceutical Inc. (BMRN)
  • CSL Limited (CSL)
  • Pfizer Inc. (PFE)
  • Roche Holding AG (RHHBY)
  • Takeda Pharmaceutical Company Limited (TAK)

Market Share Percentages and Comparison:

It is difficult to provide exact market share percentages for individual companies due to the dynamic nature of the hemophilia market. However, the listed competitors represent the major players in the market, and Lisata is a newcomer with the potential to capture a significant share if its product is successful.

Competitive Advantages and Disadvantages:

Lisata's primary competitive advantage lies in its ADAPTIR™ technology platform, which enables the development of engineered protein therapeutics with potentially improved efficacy and safety profiles. However, Lisata faces competition from established players with larger market shares and more extensive commercialization experience.

Potential Challenges and Opportunities:

Key Challenges:

Lisata faces several potential challenges, including the risks associated with clinical development, competition from established players, and the need to secure regulatory approval for its product candidates.

Potential Opportunities:

Lisata also has several potential opportunities for growth, including the success of LST-002 in clinical trials, the expansion of its product portfolio into new therapeutic areas, and the formation of strategic partnerships.

Recent Acquisitions:

Lisata has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

AI-Based Rating:

Based on an AI-based fundamental analysis, Lisata Therapeutics Inc. receives a rating of 7.5 out of 10.

Justification:

This rating is driven by several factors, including the company's promising lead product candidate, LST-002, its innovative ADAPTIR™ technology platform, and its strong financial position. However, the company's clinical-stage status and competition from established players present potential risks that are reflected in the rating.

Sources and Disclaimers:

Sources:

Disclaimer:

This overview is for informational purposes only and should not be considered investment advice. Investing in early-stage companies like Lisata involves significant風險, and all investment decisions should be made with the help of a professional financial advisor.

About Lisata Therapeutics Inc.

Exchange NASDAQ
Headquaters Basking Ridge, NJ, United States
IPO Launch date 1999-03-01
President, CEO & Director Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 25
Full time employees 25

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​